Alexander Kirby

Alex joined LifeSci Consulting as an Analyst in 2026. He holds an MSc in Bioscience Innovation and Enterprise from UCL and a BSc in Biological Sciences from Durham University. His academic training provides a strong scientific foundation, complemented by hands-on experience across biotech start-ups, venture capital, and early-stage commercial strategy.

Alex has supported commercial strategy development for AI-enabled SaaS platforms at Curenetics and OncoFlow, working across both European and US markets. At Laverock Therapeutics, a cell therapy start-up, he applied financial modelling expertise to evaluate out-licensing and partnership options, delivering clear recommendations that supported the efficient advancement of the company’s immuno-oncology programmes. He subsequently applied this experience to a cell and gene therapy scouting project in collaboration with University of Birmingham Enterprise, helping to improve transparency and opportunity for researchers and founders in the space.

Alex has a particular interest in therapeutic oncology and biopharma strategy, leveraging his analytical skillset to support the successful translation of innovative therapies to market, through the optimisation of operational costs and strategy.